Merck KGaA to Buy Springworks for $3.9B

Published on 28/04/2025 at 17:58 - Modified on 28/04/2025 at 18:25

MT Newswires

+0.41%

+0.02%

German pharma company Merck is buying US biotech SpringWorks Therapeutics for $3.9B. SpringWorks makes medicines for cancer and rare diseases and is expected to give a boost to Merck's health-care division. Belen Garijo, Merck KGaA CEO joined Bloomberg Open Interest to talk about the deal.

Bloomberg videos, provided by MT Newswires

Latest news about Merck KGaA

European share rise on tech, banks boost with focus on US trade negotiations	07-07	RE
Frankfurt Stocks Close: DAX Defies US Tariff Threats Ahead of Deadline	07-07	DP
Stifel Downgrades Merck KGaA to Sell, Cuts PT	07-07	MT
MERCK KGAA : bottom of the DAX, with Stifel downgrade	07-07
Frankfurt stock market opening: DAX rises slightly - US tariffs in focus	07-07	DP
Merck KGaA Shares Approach Yearly Low After Sell Recommendation	07-07	DP
Merck KGaA completed the acquisition of SpringWorks Therapeutics, Inc. from FMR LLC, The Vanguard Group, Inc. and BlackRock, Inc. and others.	07-01	CI
Merck Seals Largest Pharma Deal in Decades	07-01	DP
Germany's Merck KGaA Closes $3.4 Billion Purchase of US-based SpringWorks	07-01	MT
Merck completes acquisition of Springworks – explores further acquisitions	07-01	DP
MERCK KGAA : UBS reiterates its Buy rating	07-01	ZD
Merck: EMD Serono Presents Results On Efficacy And Safety Of Enpatoran	06-12	RE
China's Center for Drug Evaluation Accepts Merck KGaA's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor	06-10	CI
Merck: FDA approves Enflonsia RSV vaccine	06-10
Merck KGaA's Application to Market Tumor Treatment Pimicotinib to Be Reviewed By China	06-10	DJ
Merck KGaA Wins Chinese Approval for Tenosynovial Giant Cell Tumor Treatment	06-10	MT
China's Center For Drug Evaluation Accepts Merck KGaA, Darmstadt, Germany's Application For Marketing Authorization Of Pimicotinib	06-10	RE
Health insurers in favor of cost containment for drug spending	06-03	DP
MERCK KGAA : JP Morgan reiterates its Buy rating	06-03	ZD
MERCK KGAA : Deutsche Bank maintains a Buy rating	05-30	ZD
Merck KGaA Says Cell Tumor Inhibitor Shows Promise in Late-Stage Trial	05-28	DJ
Bernstein lowers target for Merck KGaA - 'Market Perform'	05-27	DP
MERCK KGAA : Bernstein remains Neutral	05-27	ZD
Equita Keeps Merck KGaA at Buy, Lowers PT	05-26	MT
Merck KGaA - Emd Serono Presents Positive Ph 2 Data For Enpatoran	05-21	RE